NCT04850846 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Randomly assigned participants receive a stepped dose escalation until target daily dose of 1500mg Metformin XR is reached (3 x 500mg pills/day). The intervention duration will last an additional 6 months. Metformin Extension: Participants will have the option of unblinding at the end of their 6months treatment and those who were randomly assigned to the metformin experimental arm can continue taking metformin if they opt in. The extended intervention duration will last an additional 6 months. (1500mg Metformin XR or highest tolerated dose ) Metformin XR: Orally by mouth
- id
- FG000
- title
- Metformin
- description
- Randomly assigned participants receive a stepped dose escalation until target daily dose of 3 pills/day is reached. The intervention duration will last 6 months. Placebo: Orally by mouth
- id
- FG001
- title
- Placebo
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 2
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 1
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 4
- type
- Subject stopped taking medication
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 0
- type
- Other
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 30
- group Id
- FG001
- num Subjects
- 30
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 22
- group Id
- FG001
- num Subjects
- 23
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 8
- group Id
- FG001
- num Subjects
- 7
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Randomly assigned participants receive a stepped dose escalation until target daily dose of 1500mg Metformin XR is reached (3 x 500mg pills/day). The intervention duration will last an additional 6 months. Metformin Extension: Participants will have the option of unblinding at the end of their 6months treatment and those who were randomly assigned to the metformin experimental arm can continue taking metformin if they opt in. The extended intervention duration will last an additional 6 months. (1500mg Metformin XR or highest tolerated dose ) Metformin XR: Orally by mouth
- id
- FG000
- title
- Metformin
- description
- Randomly assigned participants receive a stepped dose escalation until target daily dose of 3 pills/day is reached. The intervention duration will last 6 months. Placebo: Orally by mouth
- id
- FG001
- title
- Placebo
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 2
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 1
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 4
- type
- Subject stopped taking medication
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 0
- type
- Other
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 30
- group Id
- FG001
- num Subjects
- 30
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 22
- group Id
- FG001
- num Subjects
- 23
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 8
- group Id
- FG001
- num Subjects
- 7
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle